BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Deng L, Song Y, Young KH, Hu S, Ding N, Song W, Li X, Shi Y, Huang H, Liu W. Hepatitis B virus-associated diffuse large B-cell lymphoma: unique clinical features, poor outcome, and hepatitis B surface antigen-driven origin. Oncotarget. 2015;6:25061-25073. [PMID: 26314957 DOI: 10.18632/oncotarget.4677] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Zuccaro V, Bruno R, Arcaini L. Antiviral prophylaxis for hepatitis B carriers affected by diffuse large B cell lymphoma: a matter of survival. Br J Haematol 2021;192:11-2. [PMID: 33131046 DOI: 10.1111/bjh.17143] [Reference Citation Analysis]
2 Sunitsch S, Gilg M, Kashofer K, Leithner A, Liegl-Atzwanger B, Beham-Schmid C. Case Report: Epstein-Barr-Virus negative diffuse large B-cell lymphoma detected in a peri-prosthetic membrane. Diagn Pathol 2016;11:80. [PMID: 27539226 DOI: 10.1186/s13000-016-0533-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Huang HH, Hsiao FY, Chen HM, Wang CY, Ko BS. Antiviral prophylaxis for hepatitis B carriers improves the prognosis of diffuse large B-cell lymphoma in Taiwan - a population-based study. Br J Haematol 2021;192:110-8. [PMID: 33131074 DOI: 10.1111/bjh.17142] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
4 Chen C, Liu S, Jiang X, Huang L, Chen F, Wei X, Guo H, Shao Y, Li Y, Li W. Tumor mutation burden estimated by a 69-gene-panel is associated with overall survival in patients with diffuse large B-cell lymphoma. Exp Hematol Oncol 2021;10:20. [PMID: 33722306 DOI: 10.1186/s40164-021-00215-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
5 Xu YQ, Chen W, Shen HY, Dong SL, Li J, Li KR, Li ZY, Zhu F, Xu KL. [The clinical characteristics and viral reactivation in B cell non-Hodgkin's lymphoma patients with hepatitis B virus infection]. Zhonghua Xue Ye Xue Za Zhi 2021;42:514-7. [PMID: 34384160 DOI: 10.3760/cma.j.issn.0253-2727.2021.06.013] [Reference Citation Analysis]
6 Liu Z, Li S, Guo W, Wang Y, Wang M, Bai O. MYC Gene Rearrangements Are Closely Associated with Poor Survival of Diffuse Large B Cell Lymphoma with Hepatitis B Virus Infection. Biomed Res Int 2017;2017:1967648. [PMID: 29209623 DOI: 10.1155/2017/1967648] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
7 Zhao X, Guo X, Xing L, Yue W, Yin H, He M, Wang J, Yang J, Chen J. HBV infection potentiates resistance to S-phase arrest-inducing chemotherapeutics by inhibiting CHK2 pathway in diffuse large B-cell lymphoma. Cell Death Dis 2018;9:61. [PMID: 29352124 DOI: 10.1038/s41419-017-0097-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
8 Yu F, Huang Y, Wang Y, Yu Z, Li X, Dong J. Very late onset post-transplant diffuse large B cell lymphoma in a liver transplant recipient with hepatitis B: A case report. Medicine (Baltimore). 2018;97:e13063. [PMID: 30383683 DOI: 10.1097/md.0000000000013063] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Sun R, Medeiros LJ, Young KH. Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine. Mod Pathol 2016;29:1118-42. [PMID: 27363492 DOI: 10.1038/modpathol.2016.92] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
10 Tajima K, Takahashi N, Ishizawa K, Murai K, Akagi T, Noji H, Sasaki O, Wano M, Itoh J, Kato Y, Scichishima T, Ishida Y, Harigae H, Sawada K; Tohoku Hematology Forum. High prevalence of diffuse large B-cell lymphoma in occult hepatitis B virus-infected patients in the Tohoku district in Eastern Japan. J Med Virol 2016;88:2206-10. [PMID: 27219865 DOI: 10.1002/jmv.24584] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
11 Rong X, Wang H, Ma J, Pan S, Wang H, Jing S, Su Y, Wang L, Zhao C. Chronic hepatitis B virus infection is associated with a poorer prognosis in diffuse large B-cell lymphoma: a meta-analysis and systemic review. J Cancer 2019;10:3450-8. [PMID: 31293649 DOI: 10.7150/jca.31033] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
12 Venturutti L, Melnick AM. The dangers of déjà vu: memory B cells as the cells of origin of ABC-DLBCLs. Blood 2020;136:2263-74. [PMID: 32932517 DOI: 10.1182/blood.2020005857] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
13 Liu Z, Li S, Liu Y, Guo W, Bai O. PD1 is highly expressed in diffuse large B-cell lymphoma with hepatitis B virus infection. PLoS One 2017;12:e0180390. [PMID: 28662185 DOI: 10.1371/journal.pone.0180390] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
14 Qi X, Gui X, Zhuang K. Establishment and characterization of HBV-associated B lymphocytes with an immortalization potential. PLoS One 2019;14:e0217161. [PMID: 31120924 DOI: 10.1371/journal.pone.0217161] [Reference Citation Analysis]
15 Law MF, Ho R, Cheung CK, Tam LH, Ma K, So KC, Ip B, So J, Lai J, Ng J, Tam TH. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy. World J Gastroenterol 2016; 22(28): 6484-6500 [PMID: 27605883 DOI: 10.3748/wjg.v22.i28.6484] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 39] [Article Influence: 7.3] [Reference Citation Analysis]
16 Zhou X, Wuchter P, Egerer G, Kriegsmann M, Mataityte A, Koelsche C, Witzens-Harig M, Kriegsmann K. Role of virological serum markers in patients with both hepatitis B virus infection and diffuse large B-cell lymphoma. Eur J Haematol 2019;103:410-6. [PMID: 31338887 DOI: 10.1111/ejh.13300] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
17 Ren W, Ye X, Su H, Li W, Liu D, Pirmoradian M, Wang X, Zhang B, Zhang Q, Chen L, Nie M, Liu Y, Meng B, Huang H, Jiang W, Zeng Y, Li W, Wu K, Hou Y, Wiman KG, Li Z, Zhang H, Peng R, Zhu S, Pan-Hammarström Q. Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma. Blood 2018;131:2670-81. [PMID: 29545328 DOI: 10.1182/blood-2017-11-817601] [Cited by in Crossref: 31] [Cited by in F6Publishing: 37] [Article Influence: 7.8] [Reference Citation Analysis]
18 Cheng CL, Fang WQ, Lin YJ, Yuan CT, Ko BS, Tang JL, Tien HF. Hepatitis B surface antigen positivity is associated with progression of disease within 24 months in follicular lymphoma. J Cancer Res Clin Oncol 2021. [PMID: 34228224 DOI: 10.1007/s00432-021-03719-y] [Reference Citation Analysis]
19 Visentini M, Casato M. HBV messing with the B-cell genome leads to DLBCL. Blood 2018;131:2602-3. [PMID: 29903868 DOI: 10.1182/blood-2018-05-847525] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Lu TX, Wu S, Cai DY, Hong TT, Zhang Y, Gao HQ, Hua HY, Wu XH. Prognostic significance of serum aspartic transaminase in diffuse large B-cell lymphoma. BMC Cancer 2019;19:553. [PMID: 31176361 DOI: 10.1186/s12885-019-5758-2] [Reference Citation Analysis]
21 Zhang MY, Gao F, Zhao YW, Ni BW, Huang HH, Hou J. Inferior survival and frequent hepatic dysfunction in non-Hodgkin's lymphoma patients with HBV infection: a systematic review and meta-analysis. Hematology 2022;27:70-9. [PMID: 34957924 DOI: 10.1080/16078454.2021.2011546] [Reference Citation Analysis]
22 Chen DG, Chen G, Wang C, Ke LF, Wu H, He HM, Yang Y, Chen YP. Clinicopathological and prognostic features of hepatitis B virus-associated diffuse large B-cell lymphoma: a single-center retrospective study in China. Infect Agent Cancer 2021;16:57. [PMID: 34404436 DOI: 10.1186/s13027-021-00396-x] [Reference Citation Analysis]
23 Cheng CL, Huang SC, Chen JH, Wei CH, Fang WQ, Su TH, Yuan CT, Liu JH, Chuang MK, Tien HF. Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era. Oncologist 2020;25:793-802. [PMID: 32275807 DOI: 10.1634/theoncologist.2019-0756] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
24 Wang C, Xia B, Ning Q, Zhao H, Yang H, Zhao Z, Wang X, Wang Y, Yu Y, Zhang Y. High prevalence of hepatitis B virus infection in patients with aggressive B cell non-Hodgkin's lymphoma in China. Ann Hematol 2018;97:453-7. [PMID: 29188315 DOI: 10.1007/s00277-017-3188-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
25 Wang Y, Wang H, Pan S, Hu T, Shen J, Zheng H, Xie S, Xie Y, Lu R, Guo L. Capable Infection of Hepatitis B Virus in Diffuse Large B-cell Lymphoma. J Cancer 2018;9:1575-81. [PMID: 29760795 DOI: 10.7150/jca.24384] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
26 Lau KCK, Burak KW, Coffin CS. Impact of Hepatitis B Virus Genetic Variation, Integration, and Lymphotropism in Antiviral Treatment and Oncogenesis. Microorganisms 2020;8:E1470. [PMID: 32987867 DOI: 10.3390/microorganisms8101470] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
27 Han van Krieken J. New developments in the pathology of malignant lymphoma: a review of the literature published from May 2015-September 2015. J Hematop 2015;8:225-34. [PMID: 26640600 DOI: 10.1007/s12308-015-0262-3] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
28 Lemaitre M, Brice P, Frigeni M, Hermine O, Arcaini L, Thieblemont C, Besson C. Hepatitis B virus-associated B-cell non-Hodgkin lymphoma in non-endemic areas in Western Europe: Clinical characteristics and prognosis. J Infect 2020;80:219-24. [PMID: 31846632 DOI: 10.1016/j.jinf.2019.12.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
29 Wu J, Miao Y, Qian C, Tao P, Wang X, Dong X, Li X, Lou J, Liang J, Xu W, Li J, Min H. Clinical characteristics and outcomes in HIV-associated diffuse large B-cell lymphoma in China: A retrospective single-center study. J Cancer 2021;12:2903-11. [PMID: 33854591 DOI: 10.7150/jca.51027] [Reference Citation Analysis]
30 Zhang L, Yuan XL, Jiang L, Yang J, Guo JM, Shi J, Lei PC, Zhang Y, Zhu ZM. [Analysis of clinical characteristics and prognostic factors in patients with non-Hodgkin lymphoma and HBV infection]. Zhonghua Xue Ye Xue Za Zhi 2018;39:563-8. [PMID: 30122015 DOI: 10.3760/cma.j.issn.0253-2727.2018.07.007] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
31 Huang H, Li Z, Huang C, Rao J, Xie Q, Cui W, Tou F, Zheng Z. CD5 and CD43 Expression are Associate with Poor Prognosis in DLBCL Patients. Open Med (Wars). 2018;13:605-609. [PMID: 30519638 DOI: 10.1515/med-2018-0089] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
32 Fang X, Young KH. Hepatitis B virus antibody status provides new insights in diffuse large B-Cell lymphoma. Leuk Lymphoma 2021;62:1281-3. [PMID: 33648420 DOI: 10.1080/10428194.2021.1891233] [Reference Citation Analysis]
33 Geyer JT, Prakash S, Orazi A. B-cell neoplasms and Hodgkin lymphoma in the spleen. Semin Diagn Pathol 2021;38:125-34. [PMID: 32839024 DOI: 10.1053/j.semdp.2020.08.002] [Reference Citation Analysis]
34 Kang X, Bai L, Han C, Qi X. Clinical Analysis and Prognostic Significance of Hepatitis B Virus Infections with Diffuse Large B-Cell Lymphoma. Cancer Manag Res 2020;12:2839-51. [PMID: 32425598 DOI: 10.2147/CMAR.S244381] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
35 Picardi M, Giordano C, Della Pepa R, Pugliese N, Leone A, Delle Cave G, Iula R, Pane F, Gentile G. Regarding "Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era". Oncologist 2021;26:e1083-4. [PMID: 33559286 DOI: 10.1002/onco.13710] [Reference Citation Analysis]
36 Zhang J, Weng Z, Huang Y, Li M, Wang F, Wang Y, Rao H. High-grade B-Cell Lymphoma With MYC, BCL2, and/or BCL6 Translocations/Rearrangements: Clinicopathologic Features of 51 Cases in a Single Institution of South China. Am J Surg Pathol 2020;44:1602-11. [PMID: 32991338 DOI: 10.1097/PAS.0000000000001577] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]